[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360214-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360214-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","machine-learning-driven-drug-repurposing-for-her2-positive-breast-cancer","Machine learning-driven drug repurposing for HER2-positive breast cancer","","Machine-learning driven drug repurposing targets HER2-positive breast cancer, a subtype marked by aggressiveness and resistance to targeted therapies. A predictive framework was built to identify new HER2 inhibitors among FDA-approved drugs using 13,944 HER2 bioactivity records from BindingDB. Optimized descriptors and feature selection enabled a Random Forest model (R²=0.81; RMSE=0.86; MAE=0.6483) for high-accuracy virtual screening of 4,099 FDA drugs. Docking and molecular dynamics highlighted FDA0870 (timolol maleate) as a top dual inhibitor, with stable interactions and supportive RMSD trends, while ADMET indicated drug-like properties and acceptable safety, supporting further development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/machine-learning-driven-drug-repurposing-for-her2-positive-breast-cancer/360214/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/machine-learning-driven-drug-repurposing-for-her2-positive-breast-cancer/360214.png","ImageObject",300,407,{"name":42,"@type":43},"Cipher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal for HER2-positive breast cancer?","Question",{"text":63,"@type":64},"To use a machine-learning framework to identify promising HER2 inhibitors by repurposing FDA-approved drugs, with computational validation through docking, molecular dynamics, and ADMET analysis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What dataset and modeling approach were used to build the predictive models?",{"text":68,"@type":64},"The models were trained on 13,944 HER2 bioactivity records from BindingDB. After optimizing descriptors and reducing dimensionality, a Random Forest model using 75 optimized descriptors achieved strong predictive performance.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is FDA0870 highlighted, and what evidence supports it?",{"text":72,"@type":64},"FDA0870 (timolol maleate) consistently ranked as a top dual inhibitor in docking against both HER2 wild-type and an exon-20 insertion mutant. Molecular dynamics supported complex stability through RMSD trends and persistent residue interactions, and ADMET suggested favorable drug-like and safety properties.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360214,1790318485,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMachine learning-driven drug repurposing for HER2-positive breast cancer  \nBasavana Gowda Hosur Dinesh1, Srinivas Ganjipete1, Bandral Sunil Kumar1, Damodar NayakAmmunje2, Selvaraj Kunjiappan3, Prabu Kumar Seetharaman4, Mohankumar Ramar5, Kumarappan Chidambaram6 & Parasuraman Pavadai1􀀍  \nBreast cancer, particularly the Human Epidermal Growth Factor Receptor 2 (HER2)-positive subtype, remains a significant clinical challenge due to its aggressive nature and the frequent development of resistance to targeted therapy. In this study, we created a comprehensive machine-learning (ML) -based drug repurposing framework to identify new HER2 inhibitors among FDA-approved drugs. A carefully curated dataset of 13,944 HER2 bioactivity records from BindingDB was used to build high-accuracy predictive models. This involved optimizing descriptors, reducing dimensionality, and selecting key features. The Random Forest model trained on 75 optimized descriptors demonstrated the best performance (R² = 0.81, RMSE = 0.86, MAE = 0.6483). This allowed us to understand structureactivity relationships and perform reliable virtual screening of 4,099 FDA-approved drugs. Docking studies against HER2 wild-type (7PCD) revealed strong interactions, with scores from-10.5 to-7.5 kcal/ mol. For the exon-20 insertion mutant (8U8X), the affinities were even higher (-11.6 to-8.0 kcal/ mol), exceeding the reference co-crystal ligand in both cases. FDA0870 (Timolol maleate) consistently ranked as a top dual inhibitor, forming stable hydrogen bonds and hydrophobic contacts with key catalytic residues of both wild-type and mutant HER2 . Molecular dynamics simulations supported its stability, with wild-type HER2-FDA0870 complexes showing an average protein RMSD of 3.4 Å and a ligand RMSD of 2.9 Å, whereas mutant complexes had an average protein RMSD of 3.9 Å and a ligand RMSD of 2.1 Å over extended trajectories. Persistent interactions with residues such as ASP863/ ASP867, THR862/THR866, and LYS753 were observed. ADMET analysis indicated that the drug had good drug-like properties, moderate permeability, a high unbound fraction, and acceptable safety features, suggesting its potential for further development. This integrated ML, docking, MD, and ADMET approach demonstrates that FDA0870 is a promising repurposed dual inhibitor for HER2-positive and HER2-mutant breast cancer, highlighting the value of computational pipelines in speeding up the search for targeted cancer therapies.  \nKeywords Breast cancer, HER2 wild and mutated type, Machine learning, Molecular docking, Dynamicsand ADMET  \nGlobally, breast cancer is considered one of the most pertinent health issues affecting women, as it accounts for a large number of cancer-related deaths1. Based on GLOBOCAN 2022 data by the International Agency for Research on Cancer (IARC), it is depicted that breast cancer is the most diagnosed cancer globally, with 2.3 million new cases, which contributes to 11.7% of total cancers diagnosed2. It also results in about 685 thousand deaths annually3. Such factors as population growth, lifestyle changes, hormonal factors, and inadequate access to healthcare lead to an increase in the incidence of breast cancer4. Hence, even though gradual improvements are being made on various fronts, the disease remains a major public health issue bar none worldwide. These tendencies indicate the need to work more actively on improving the prevention and treatment system5.  \n1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bengaluru, Karnataka 560054, India. 2Department of Pharmacology, Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bengaluru, Karnataka 560054, India. 3Department of Biotechnology, Alliance University, Anekal, Bengaluru, Karnataka 562106, India. 4Laboratory of Functional Molecules and Materials, School of Physics and Optoelectroni","cbCaingv5Vru8U5M","https://ap.wps.com/l/cbCaingv5Vru8U5M","pdf",3033009,18,"English","# Introduction\n## Disease challenge and resistance to targeted therapy\n## Global burden and risk factors\n## Precision medicine and HER2-positive subtype\n## Research objective and computational pipeline","[{\"question\":\"What is the study’s main goal for HER2-positive breast cancer?\",\"answer\":\"To use a machine-learning framework to identify promising HER2 inhibitors by repurposing FDA-approved drugs, with computational validation through docking, molecular dynamics, and ADMET analysis.\"},{\"question\":\"What dataset and modeling approach were used to build the predictive models?\",\"answer\":\"The models were trained on 13,944 HER2 bioactivity records from BindingDB. After optimizing descriptors and reducing dimensionality, a Random Forest model using 75 optimized descriptors achieved strong predictive performance.\"},{\"question\":\"Why is FDA0870 highlighted, and what evidence supports it?\",\"answer\":\"FDA0870 (timolol maleate) consistently ranked as a top dual inhibitor in docking against both HER2 wild-type and an exon-20 insertion mutant. Molecular dynamics supported complex stability through RMSD trends and persistent residue interactions, and ADMET suggested favorable drug-like and safety properties.\"}]","Machine learning-driven drug repurposing for HER2-positive breast cancer | PDF",1790139081,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/413593898d7d8a8e3bd520757bf5aa26.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca1c59eb11f57f8924f2d7fe83da7476.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c2b4f00871aaf061a53e82554b124b2.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2214a83ab8988c3b24170cb42e8d4e22.webp",980,1287]